© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Experts review prostate cancer clinical cases and discuss approaches to treating patients with PSMA targeted therapies.
June 10th 2022
Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.
July 1st 2022
Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.
Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
July 8th 2022
Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.
A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.
July 18th 2022
A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.
Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.
July 26th 2022
Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.
A review of recent data from the TheraP trial.
July 29th 2022
Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.